CA
NZ
UK
AU
IND
US
Under the Elevar agreement, Relay had received USD 18.7 million as of September 30, made up of USD 5.0 million at signing, USD 3.7 million for transfer of materials and USD 10.0 million in milestone payments. It remains eligible for up to USD 485.0 …
Because of the pending transaction, the company said it is suspending quarterlyEarningsconference calls and is no longer providing quarterly or annual guidance. The company described its strategic focus as the Intelligent Product Lifecycle vision.
Comparable RevPAR was USD 153.36, up 9.7% from the prior year. Comparable average daily rate was USD 203.35, up 6.4%, and comparable occupancy was 75.4%, compared with 73.1% a year earlier. Non-room revenues rose 6.5%, which the company tied to corporate transient and groupDemandand …
The company describes its platforms as spanning handsets, automotive, IoT and data center, built on Snapdragon, Dragonwing and Dragonfly products.Research and Developmentexpense was USD 10.21 billion against USD 9.04 billion, and the company citedInvestmentin theData Centerbusiness, higher employee costs and lower engineering cost reimbursements.
Management said the direct channel is tuned to bid for high-intent shoppers while balancing competitive prices against target unit economics, while the partnership channel gives access to customers inside partner experiences. Gross premiums written were USD 357.5 million against USD 387.2 million, which the …
Financial Services revenue was USD 270.96 million, against USD 207.48 million a year earlier. Chief executive Doug Valenti said carrierDemandin auto insurance continued and broadened, and that the company made progress widening its footprint with those clients.
Fee-related revenue was stated as 17% higher than a year earlier. Fee-related earnings were USD 43.0 million, up 19%, with a fee-related earningsMarginof 48%. Adjusted net income was USD 32.3 million, a 13% increase.
The company has not generated revenue from product sales since inception and reported none in the quarter. It recognized collaboration arrangement revenue in earlier years under agreements tied to Horizon Therapeutics, which were later terminated and amended. In November 2025 the company sold substantially …
The company described the plan as designed to simplify operations and align resources with its core platform. Restructuring charges were USD 9.99 million in the quarter and USD 11.66 million for the nine months.
The October 2026 offerings included 9,761,905 shares at USD 21.00 and pre-funded warrants for up to 1,190,476 shares, with net proceeds of approximately USD 215.7 million. A separate offering of USD 172.5 million of 2.25% convertible senior notes due December 1, 2032 had net …
Please wait processing your request...